Arrowhead Pharmaceuticals, Inc.
Feb 6, 2017

Arrowhead Reports Fiscal 2017 First Quarter Results

- Conference Call and Webcast Today at 4:30 p.m. EST

PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2017 first quarter ended December 31, 2016. The company is hosting a conference call at 4:30 p.m. EST to discuss results.

Conference Call and Webcast Details

Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 59701860.

A replay of the webcast will be available on the company's website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 404-537-3406 and enter Conference ID 59701860.

Selected Fiscal 2017 First Quarter and Recent Events

Selected Fiscal 2017 First Quarter Financial Results

ARROWHEAD PHARMACEUTICALS, INC.
CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited)
 
  Three Months Ended
December 31,

OPERATING SUMMARY

  2016       2015  
 
REVENUE $ 4,365,496 $ 43,750
OPERATING EXPENSES
Research and development 9,527,051 10,338,833
Salaries and payroll-related costs 4,276,105 3,919,886
General and administrative expenses 1,854,174 1,951,609
Stock-based compensation 2,424,442 2,380,343
Depreciation and amortization   1,185,611     794,349  
TOTAL OPERATING EXPENSES   19,267,383     19,385,020  
OPERATING LOSS (14,901,887 ) (19,341,270 )
OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES   2,815,779     76,856  
NET LOSS $ (12,086,108 ) $ (19,264,414 )
 
EARNINGS PER SHARE (BASIC AND DILUTED): $ (0.17 ) $ (0.32 )
WEIGHTED AVERAGE SHARES OUTSTANDING   71,444,600     59,548,672  
 

FINANCIAL POSITION SUMMARY

December 31, September 30,

 

  2016     2016  
 
CASH AND CASH EQUIVALENTS 102,105,569 85,366,448
OTHER ASSETS   42,152,537     42,810,057  
TOTAL ASSETS   144,258,106     128,176,505  
TOTAL LIABILITIES 47,049,685 33,152,246
TOTAL STOCKHOLDERS' EQUITY   97,208,421     95,024,259  
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY   144,258,106     128,176,505  
 
SHARES OUTSTANDING 74,413,040 69,746,685
 

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investor Relations:
The Trout Group
Chad Rubin
646-378-2947
ir@arrowheadpharma.com
or
Media:
Russo Partners
Rich Allan
646-942-5588
rich.allan@russopartnersllc.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media